Encare offers an interactive SaaS solution that supports healthcare providers in improving recovery for patients after surgical procedures. The innovative solution empowers healthcare providers to adhere to international treatment guidelines throughout the entire patient care continuum — from initial diagnosis and preparation to surgery and rehabilitation, contributing to significant cost savings in the global healthcare sector.
In her role, Lotta Sellén will work on the continued global expansion of Encare’s solution and focus on additional value creation through further development of the solution and business model. She will assume the position of CSO in December 2023.
Lotta Sellén holds a Master’s degree in Chemical Engineering from Chalmers University of Technology and an MBA from the University of Gothenburg. She brings extensive experience from various roles in the pharmaceutical industry, including management consulting in healthcare as well as business development and strategy in e-health.
“We are very excited to have Lotta join our team. I have had the opportunity to work with Lotta in the past and know that Lotta has exactly the skills that Encare needs as we gear up for further expansion. Simultaneously, we are preserving crucial expertise within the company as our current CSO, Marie Monier, transitions into another role with an increased focus on engaging with both our existing and new customers,” says Rasmus Waller, CEO at Encare.
Why have you taken on the position of CSO at Encare, and how will you contribute to the role?
“Never has the need for healthcare been greater, and the pandemic has taught us that resources are finite and needs are infinite, not least in surgical operations.
What I am passionate about, and what has been a common thread in my career, is developing products or services that contribute to improved public health. This can involve the development of services, processes, and infrastructure that provide access to healthcare under new and improved conditions compared to before.
With my experience, I can further contribute to the dialogue with Encare’s customers by enhancing the understanding of the complexity of healthcare. I can translate the prerequisites necessary for more healthcare organizations to embrace evidence-based practices. This way, the patients they care for can be given the best conditions. I aim to be the customer’s voice to enable expansion, both in terms of product development and how the product is used.”
What strategic initiatives are on the agenda for you and for Encare in the coming years?
“I see potential in three areas that share collaboration as the common theme: integrated care systems, new medical fields and technological integration:
- Integrated healthcare systems: This represents a clear strategic direction in several important markets and Encare’s solution offers a scalability that aligns seamlessly with that development. A region with several hospitals and cooperating levels of care can together create large benefits in improved quality and consequently cost savings. By engaging in discussion at the healthcare system level, we can reach more users and assist our customers in maximizing their benefits.
- New medical fields: Standardization and compliance with guidelines is a clear strategic focus supported by Encare’s solution. In the long term, Encare’s concept for perioperative care can also be developed for other areas where evidence-based guidelines or regulatory requirements exist. This requires a collaborative partner that develops guidelines and holds global legitimacy.
- Technical integration: Encare’s customers operate in a challenging reality concerning finances and resources, a challenge shared by other providers in our industry. If we can reduce the time required to capture the necessary data, it is likely a significant benefit that holds substantial value for users and, consequently, customer satisfaction. Both the number of systems and level of integration are factors to evaluate to set the right ambition when developing a marketable and sellable product.”